NEW YORK (GenomeWeb News) – Exiqon today said that it will divest its California-based CLIA lab, Oncotech, in an effort to "gain operational and infrastructural efficiencies and to free up human financial resources."

The Vedbaek, Denmark-based molecular diagnostics firm also said that as a consequence of the divestiture it would seek partners to co-develop and commercialize its miRNA-based diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.